Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.

For patients with chronic viral hepatitis ... Researchers in India evaluated 1387 adults with asymptomatic hepatitis B virus (HBV) infection to determine the correlation between liver-enzyme ...

Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) clinical data from ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

may shortly become the primary treatment of choice for patients with chronic hepatitis B.

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos”), a clinical ...

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen ... Data from the B-Clear study also showed that patients with low baseline HBsAg levels were most likely to benefit ...

Dr Casey Means, who went from physician to wellness influencer, could hold one of the top medical positions in America.